These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 523359)
21. [Basis of antifungal chemotherapy]. Arai T; Uno H Nihon Saikingaku Zasshi; 1983; 38(2):525-48. PubMed ID: 6350637 [No Abstract] [Full Text] [Related]
22. [New aspects in treatment of systemic mycoses]. Presterl E; Graninger W Wien Klin Wochenschr; 1998 Nov; 110(21):740-50. PubMed ID: 9871965 [TBL] [Abstract][Full Text] [Related]
23. Caspofungin for invasive fungal infections: combination treatment with liposomal amphotericin B in children undergoing hemopoietic stem cell transplantation. Pancham S; Hemmaway C; New H; Albert E; Dokal I; Roberts IA; McCloy M Pediatr Transplant; 2005 Apr; 9(2):254-7. PubMed ID: 15787803 [TBL] [Abstract][Full Text] [Related]
24. N, N, N-trimethylamphotericin B methyl ester chloride (DMS-AME): in vitro and in vivo antifungal activity studies in comparison with fungizone. Zaremba M; Borowski J; Feliński J; Rozkiewicz D; Rozkiewicz M; Zaremba K; Czerwiński A; Borowski E J Chemother; 1989 Jul; 1(4 Suppl):243-5. PubMed ID: 16312386 [No Abstract] [Full Text] [Related]
25. The multitude of targets for the immune system and drug therapy in the fungal cell wall. Nimrichter L; Rodrigues ML; Rodrigues EG; Travassos LR Microbes Infect; 2005 Apr; 7(4):789-98. PubMed ID: 15823515 [TBL] [Abstract][Full Text] [Related]
27. Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections. Groll AH; Walsh TJ Mycoses; 2006; 49 Suppl 1():7-16. PubMed ID: 16961576 [TBL] [Abstract][Full Text] [Related]
28. Human mycoses: drugs and targets for emerging pathogens. Georgopapadakou NH; Walsh TJ Science; 1994 Apr; 264(5157):371-3. PubMed ID: 8153622 [No Abstract] [Full Text] [Related]
29. Efficacy of amphotericin B or amphotericin B-intralipid in combination with caspofungin against experimental aspergillosis. Sionov E; Mendlovic S; Segal E J Infect; 2006 Aug; 53(2):131-9. PubMed ID: 16360214 [TBL] [Abstract][Full Text] [Related]
30. Managing the challenges of invasive fungal infections. Herbrecht R Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():1-2. PubMed ID: 16701981 [No Abstract] [Full Text] [Related]
31. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624 [TBL] [Abstract][Full Text] [Related]
32. New challenges to the therapy of systemic fungal infections. Medoff G Trans Am Clin Climatol Assoc; 1996; 107():146-57; discussion 157-8. PubMed ID: 8725568 [TBL] [Abstract][Full Text] [Related]
33. [Refractory respiratory tract infections. 9. Chemotherapy of recent respiratory tract infections. d. Mycoses]. Mori T; Takahashi M; Ikemoto H Nihon Rinsho; 1987 Mar; 45(3):627-31. PubMed ID: 3298740 [No Abstract] [Full Text] [Related]
34. [Mechanisms of resistance to antifungal agents]. Makimura K Nihon Rinsho; 2007 Feb; 65 Suppl 2 Pt. 1():466-70. PubMed ID: 17455664 [No Abstract] [Full Text] [Related]
35. [Management of visceral mycoses, with special reference to drug therapy]. Ikemoto H Nihon Rinsho; 1980 Nov; 38(11):4386-92. PubMed ID: 7253229 [No Abstract] [Full Text] [Related]
36. [Chemotherapy of mycoses of the inner organs]. Scholer HJ Schweiz Med Wochenschr; 1968 Apr; 98(16):602-11. PubMed ID: 5688589 [No Abstract] [Full Text] [Related]